Oncology – Bone and Sarcomas
German Guidelines on Sarcoma of the Uterus.
6 Dec, 2022 | 13:50h | UTCSingle-arm P2 study | Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas.
9 Nov, 2022 | 12:24h | UTCHypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
RCT | Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma.
9 Nov, 2022 | 12:12h | UTCComparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.
8 Nov, 2022 | 12:00h | UTC
Single-arm phase 2 study | Activity of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.
22 Aug, 2022 | 11:53h | UTCActivity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) – JAMA Oncology (free for a limited period)
Invited Commentary: Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet? – JAMA Oncology (free for a limited period)
Single-center phase 2 trial | Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas.
11 Aug, 2022 | 11:52h | UTCDurvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK pic.twitter.com/BP7fz9FWRw
— The Lancet Oncology (@TheLancetOncol) August 5, 2022
RCT | Doxorubicin alone vs. doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma.
20 Jul, 2022 | 11:36h | UTCDoxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Efficacy and safety of TRC105 plus pazopanib vs. pazopanib alone for treatment of patients with advanced angiosarcoma.
27 May, 2022 | 11:15h | UTCCommentaries:
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post
Commentaries on Twitter
A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx
— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022
First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2
— JAMA Oncology (@JAMAOnc) March 31, 2022
RCT: Selinexor in advanced, metastatic dedifferentiated liposarcoma.
12 Apr, 2022 | 08:24h | UTC
Guidelines for diagnosing incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS).
4 Apr, 2022 | 00:45h | UTC
Commentary on Twitter (article and images under a http://creativecommons.org/licenses/by-nc/4.0/)
Bone RADS- White Paper from @SkeletalRadiol
Want to know how to handle bone lesions? Take a look – open access:https://t.co/mBUFzgJiCf@cychang1414 @ahlawat_shivani @HillaryGarnerMD@mbucknor @Radsdoc82 @behrangamini @IKhodarahmi @JimWuMSK
Apologies couldn't find all authors pic.twitter.com/hL8r04uK40— Adam Singer, MD (@AdamSingerMD) April 1, 2022
Educational Review: Multiparametric MRI evaluation of bone sarcomas in children.
3 Mar, 2022 | 07:54h | UTCMultiparametric MRI evaluation of bone sarcomas in children – Insights into Imaging
RCT: Prolonging prophylactic intravenous antibiotic regimens not beneficial after endoprosthetic reconstruction for lower extremity bone tumors.
19 Jan, 2022 | 08:37h | UTCCommentary: No Benefit Seen With Longer Antibiotic Course After Surgery for Bone Tumors – Cancer Therapy Advisor
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.
1 Oct, 2021 | 09:57h | UTC
ASTRO Guideline: Radiation therapy for treatment of soft tissue sarcoma in adults.
29 Jul, 2021 | 10:54h | UTCNews release: Astro Issues Clinical Guideline on Radiation Therapy for Soft Tissue Sarcoma in Adults
ESMO Guidelines: Soft tissue and visceral sarcomas.
29 Jul, 2021 | 10:53h | UTC
Meta-analysis: Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases
20 Jan, 2021 | 01:09h | UTC